Keywords: Contrast Agents, Contrast Agents, NaGdF4 nanoparticles, Tumor targeting peptide, Magnetic resonance imaging, Positron emission tomography, Multimodal imaging
Motivation: There are still rare multi-modality contrast agents or probes that can enhance both the signals of PET and MRI synchronously in clinical.
Goal(s): We developed a strategy of synchronous PET/MR diagnosis of tumor based on 68Ga-NaGdF4@RGD nanoprobes.
Approach: The in vivo PET/MR multimodal simultaneous imaging capability of 68Ga-NaGdF4-RGD nanoparticles was validated by a wider variety of tumor models. Additionally, the relationship between the targeting effect and integrin αvβ3 expression levels was explored.
Results: The fact suggested that 68Ga-NaGdF4-RGD probes possessed satisfying tumor-specific targeting ability . The level of enrichment of the nanoprobes was found to reflect the expression level of integrin αvβ3 in tumors.
Impact: This study successfully achieved simultaneous PET/MR multimodal imaging, which significantly improves the diagnostic accuracy of tumour. The radioactivity uptake of can reflect the integrin αvβ3 expression level of the tumour, and PET/MR is expected to be used for tumour staging.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords